Events & Presentations

Date	Event Details
Nov 23, 2020 4:30 PM EST	Arrowhead Pharmaceuticals 2020 Year End Results Listen to webcast Supporting Materials: Prepared Remarks 194.2 KB
Nov 19, 2020 1:30 PM EST	ARO-ANG3 KOL Webinar Register for webcast Supporting Materials: ARO-ANG3 KOL Webinar Slides 2.1 MB View Additional Information KOL: Ira Goldberg, M.D., New York University Langone School of Medicine
Nov 18, 2020 11:30 AM EST	ARO-APOC3 KOL Webinar Register for webcast Supporting Materials: ARO-APOC3 KOL Webinar Slides 2 MB View Additional Information KOL: Christie Ballantyne, M.D., Baylor College of Medicine
Nov 17 - Nov 19, 2020	Jefferies Virtual London Healthcare Conference Register for webcast View Additional Information November 19, 2020, 2:40 p.m. GMT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation.
Nov 13 - Nov 16, 2020	The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) Supporting Materials: ARO-AAT reduces serum and intra-hepatic Z-AAT protein in PiZZ alpha-1 antitrypsin deficient patients with liver disease leading to improvements in clinically relevant liver biomarkers 943.8 KB View Additional Information Title: ARO-AAT Reduces Serum and Intra-hepatic Z-AAT Protein in PIZZ Alpha-1 Antitrypsin Deficient Patients with Liver Disease Leading to Improvements in Clinically Relevant Liver Biomarkers Authors: Pavel Strnad, et al. Publication Number: LP14 Session: Late-breaking Abstract Posters
Nov 13 - Nov 17, 2020	American Heart Association (AHA) Scientific Sessions 2020 Supporting Materials: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with dyslipidemia 348.4 KB Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia 679 KB Safety, Tolerability, and Efficacy of Single-dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a) 325 KB View Additional Information Title: Pharmacodynamic effect of ARO-ANG3, an investigational RNA interference therapeutic targeting hepatic angiopoietin-like protein 3, in patients with hypercholesterolemia Authors: Gerald F. Watts, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD Title: Pharmacodynamic effect of ARO-APOC3, an investigational hepatocyte-targeted RNA interference therapeutic targeting apolipoprotein C3, in patients with hypertriglyceridemia and multifactorial chylomicronemia Authors: Christie Ballantyne, presenting on behalf of Peter Clifton, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD Title: Safety, Tolerability and Efficacy of Single-Dose AMG 890, a Novel siRNA Targeting Lp(a), in Healthy Subjects and Subjects with Elevated Lp(a) Authors: Michael J. Koren, et al. Session: Advances in Understanding and Treatment of Dyslipidemia and New Therapies for CVD
Oct 8, 2020 8:30 AM EDT	Arrowhead/Takeda Collaboration Call Listen to webcast Supporting Materials: Prepared Remarks 164.7 KB
Oct 6, 2020 1:30 PM EDT	Chardan Virtual 4th Annual Genetic Medicines Conference Register for webcast View Additional Information Vince Anzalone, CFA, Arrowhead’s vice president and head of investor relations, will participate in a fireside chat presentation
Sep 15, 2020 2:00 PM EDT	Cantor Fitzgerald Global Healthcare Conference 2020 Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation
Sep 15, 2020 9:30 AM EDT	H.C. Wainwright 22nd Annual Global Investment Conference Listen to webcast View Additional Information Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation